second single acquisition generated a non-contrast CT of the brain, multiphase angiography at 3 frames/second and whole-brain perfusion imaging (figure 1). The non-contrast CT showed patchy infarcts. The angiography showed a sub-occlusive left MCA thrombus with good collaterals. The perfusion imaging showed matched defects corresponding to the infarcts but no significant penumbra tissue. A standard selective left internal carotid artery catheter angiography confirmed the sub-occlusive thrombus and good collaterals. Repeat on table clinical exam had improved from admission. Given the sub-occlusive thrombus, good collaterals and no at-risk ischemic tissue on perfusion – thrombectomy was not performed.

**Conclusion** Rapid assessment of suspected LVO with simultaneous treatment is feasible in select stroke patients, e.g. transfers, using a hybrid CT-Angiography suite and direct intra-aortic diluted contrast injection. An intra-arterial injection gives superior signal-to-noise ratio and temporal resolution than intravenous injection. Immediate thrombectomy following the acquisition in the same room can shorten door to recanalization times.

**Disclosures** A. Rai: 2; C; Stryker, Microvention, Cerenovus. A. Tarabishy: None. S. Boo: 2; C; STRYKER.

**Results**

**Model 1:** Prediction of survival: mRS score of 0–5 (alive) or 6 (dead).

**Model 2:** Prediction of good/poor outcome: mRS score of 0–3 (good), or 4–6 (poor).

**Model 3:** Prediction of good/poor outcome: mRS score of 0–2 (good), or 3–6 (poor).

**Model 4:** Prediction of mRS category: mRS score of 0–2 (no disability), 3 (minor disability), 4–5 (severe disability) or 6 (dead).

The accuracy and discriminative power of each predictive model were tested.

**Results** Prediction of survival was 87% accurate (area under the curve 0.94) for Model 2 and 95% accurate (area under the curve 0.98) for Model 3. Prediction of mRS category was 74% accurate, and increased to 95% using the ‘one-score-out rule’.

**Conclusion** This novel tool-kit is easy to use and provided accurate estimations of outcome. It can be used to aid decision making and consent for mechanical thrombectomy.

**Disclosures** S. Nayak: None. H. Wright: None. A. Bazarova: None. M. Raseta: None.

**P-004**

**THROMBUS CLASSIFICATION WITH TARGETED MAGNETIC NANOPARTICLES**

C. Eskey*, W. Wells, D. Schartz, C. Jackson, J. Weaver.

**Purpose and introduction** Thromboembolic material producing large vessel occlusion of the cerebral arteries varies substantially in composition and these differences affect the ability of both intravenous thrombolysis and mechanical thrombectomy to achieve rapid arterial recanalization. The binding of targeted magnetic nanoparticles may offer a means of noninvasively determining clot composition. We hypothesize that binding of targeted magnetic nanoparticles to thrombus is measurable and varied with clot composition.

**Materials and methods** Thromboembolic material was extracted from 10 patients during emergent mechanical thrombectomy for large vessel occlusion in ICA, MCA, or basilar arteries. The nominal source of the thromboembolic material and time from onset to clot retrieval were recorded. Each sample was divided and sent both for standard histopathologic evaluation and for in vitro assessment by magnetic spectroscopy of nanoparticle Brownian rotation (MSB). The thromboembolic material was incubated in a solution of magnetic nanoparticles that had been coated with antibodies directed toward thrombin. Nanoparticle binding was measured using magnetic relaxometry.

**Results** All clots bound measurable quantities of the thrombin-directed magnetic nanoparticles. 2/10 of the samples were composed of >90% fibrin material. These two samples demonstrated much higher than expected nanoparticle binding. The other samples had proportions of thrombus that ranged from 50 to 60%. Among these samples there was a significant correlation between nanoparticle weight and RBC content (R² = 0.70, p<0.04) and a lesser association between nanoparticle relaxometry and RBC content (R² = 0.49, p<0.12).

**Discussion** Thrombin-directed nanoparticles bound thrombin-rich thromboembolic material roughly in proportion to the RBC content, as expected, confirming an affinity of these particles for this component of the clot. However, samples consisting almost exclusively of fibrin bound even higher levels of the nanoparticles suggesting the presence of an additional binding mechanism.

**Disclosures** C. Eskey: None. W. Wells: None. D. Schartz: None. C. Jackson: None. J. Weaver: None.